Although a phase I trial of selective EZH2 inhibitor PF-06821497 monotherapy failed to show a treatment response in two SCLC patients [225], these preclinical findings provide a rationale for further development of epigenetic targeting strategies. This evidence concerns the gene EZH2 and small cell lung carcinoma.